Estrogen product tops 1996 charts
Wyeth-Ayerst's Premarin remained the most-prescribed pharmaceutical product in the United States last year, according to IMS America, Totowa, NJ.
Wyeth-Ayerst's Premarin remained the most-prescribed pharmaceutical product in the United States last year, according to IMS America, Totowa, NJ.
American Home Products, Madison, NJ, topped the list of pharmaceutical manufacturers with a total of 159.6 million prescriptions in 1996, gaining significant help from the Wyeth-Ayerst Division, Philadelphia.
IMS reported a total of 2.4 billion prescriptions dispensed in 1996, a 4% increase over 1995.
Of these, Premarin was responsible for 44.8 million prescriptions.
Although this only represents a 1% increase over Premarin prescriptions for 1995, the drug remains far and away the leader in terms of prescription volume.
Holding the lead in prescription volume among drug manufacturers, American Home Products grew 10% over 1995. In second place, New York-based Bristol-Myers Squibb held 134.3 million prescriptions, a 9% increase over the prior year.
IMS said Hoechst Marion Roussel Inc., Kansas City, MO, experienced an 11% decrease in prescription volume with 131.7 million scripts for 1996, ranking the company third. PR
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
